Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: A bus current-based short circuit fault diagnosing method for the power converter of a switched reluctance motor, which, by detecting the transient value of bus current in the power converter of a switched reluctance motor, calculates the mean value ? of maximum wavelet transform coefficient corresponding to bus current under different scale parameters and takes the mean value as a fault characteristic quantity, and utilizes a curve of mean value ? of maximum wavelet transform coefficient corresponding to bus current in the power converter of the switched reluctance motor under different scale parameters in the entire range of rotation speed to diagnose whether there is a short circuit fault in the position main switches of the power converter of the switched reluctance motor.

Abstract: A lamp bar fixation device and a backlight source provided with the lamp bar fixation device are provided. The lamp bar fixation device comprises a back plate, a positioning clamp and a spacer, wherein the back plate is provided thereon with a positioning slot for receiving a lamp bar, the positioning clamp is positioned above the positioning slot, and the spacer is detachably mounted in the positioning clamp so as to fix the lamp bar. The lamp bar fixation device effectively improves assembling efficiency of the lamp bar and has a good heat dispersion performance. Meanwhile, the lamp bar fixation device facilitates the detachment of the lamp bar, and enables the lamp bar to be replaced without a risk of being damaged, and rework performance can be improved.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.

Abstract: A method, apparatus, and system for application controlled network selection between a broadband network and a narrowband network include operating an application with an end device with a narrowband connection to the end device; acquiring a source broadband connection comprising a source broadband network address; negotiating a peer-to-peer broadband connection with the end device utilizing the narrowband connection to communicate the source broadband network address; utilizing the peer-to-peer broadband connection for data associated with the application responsive to successful negotiating; and managing the peer-to-peer broadband connection using the narrowband connection as a control channel therefor. The narrowband connection can include Digital Mobile Radio (DMR), Land Mobile Radio (LMR), Project 25 (P25), Terrestrial Trunked Radio (TETRA), or the like.

Abstract: The present invention discloses a light bar assembly and a backlight. The light bar assembly includes a light bar and a light bar fixing tape arranged on a back surface of the light bar, wherein the light bar fixing tape includes a main body part and multiple extension parts extending out from the main body part, the main body part is used for being attached to a flexible printed circuit board on the light bar, and the multiple extension parts are used for being attached to a backplane of a backlight to be assembled. The backlight includes a backplane and the light bar assembly, multiple through holes one-to-one corresponding to the positions of the multiple extension parts are formed on the backplane, and each extension part can penetrate through the corresponding through hole and be attached to the back surface of the backplane.

Abstract: A fault diagnosing method based on standard deviation of detail coefficients for the power converter of a switched reluctance motor, operates by detecting the transient value of phase current in the power converter of a switched reluctance motor, the standard deviation of detail coefficients a is calculated and is taken as a fault characteristic quantity, and then whether there is a short circuit fault in the main switch of the power converter of the switched reluctance motor is diagnosed with a curve of standard deviation of detail coefficients a of phase current in the power converter of the switched reluctance motor in the entire range of rotation speed or in the entire range of torque. The method is applicable to the power converter of a switched reluctance motor with any topological structure, with any number of phases, can diagnose short circuit faults accurately, and has a great value in engineering application.

Abstract: The invention relates to a method for synthesizing a selectively labeled RNA, and an apparatus for performing the method. Specific segments or discrete residues within the RNA may be selectively labeled, and different segments may include different labels.

Abstract: A quantitative evaluation method for the reliability of a Markov model switch reluctance motor system. The method comprises: solving a probability matrix P?T(t) of a switch reluctance motor system being in any survival state at any time t via a state conversion diagram of the switch reluctance motor system; calculating the sum of various elements of the probability matrix P?T(t) of the survival state, so that a reliability function R(t) is obtained; and thus calculating the average working time of the switch reluctance motor system before failure, thereby realizing the quantitative evaluation of the switch reluctance motor system and satisfying the requirements for the reliability analysis of a switch reluctance motor drive system. This disclosure has a good engineering application value.

Abstract: The present invention provides a compound drug-delivery precursor for membrane permeation, and a drug carrier preparation based on this precursor. The compound drug-delivery precursor and the drug carrier preparation of the present invention may effectively improve the membrane permeability of compounds with low membrane permeability and provide a new choice for clinical medication.

Abstract: The present invention discloses a cell-penetrating method for compounds, comprising the following steps of: (1) preparing raw materials, i.e., the compounds and DNA or RNA; (2) linking: linking the compounds to the DNA or RNA to obtain a molecular conjugate; and (3) transferring: transferring the molecular conjugate obtained in the step (2) into cells by a gene transfer method. The present invention further discloses a structure of a molecular conjugate for transmembrane transfer and a method for synthesizing the molecular conjugate. The method of the present invention effectively solves a problem of low membrane permeability of compounds, so that the compounds enter the cell to act on targets thereof, thus to provide a novel drug-delivery way. The method of the present invention may be used for clinical treatment by drugs with low membrane permeability.

Abstract: A method is provided that enables dispatchers in power grid control centers to manage changes by applying multi-interval dispatch. A multi-stage resource scheduling engine and a comprehensive operating plan are used. Multiple system parameter scenarios are coordinated.

Abstract: The present invention discloses a method for capturing drug targets, comprising the following steps of: (1) preparing row materials, i.e.

Abstract: Disclosed is a speaker system. The speaker system includes a multimedia unit including a plurality of speaker units, a resonance medium for supporting the multimedia unit, a number of low frequency vibrators assembled with the multimedia unit and located between the multimedia unit and the resonance medium, a driving unit for providing high frequency audio signals to the speaker units and low frequency audio signals to the low frequency vibrators. A resonance member is formed by the low frequency vibrators and the resonance medium for producing low frequency sound.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.